Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BMP Pharma Trading AGSTU:BMP 36 Peter Lynch Fair Value is €13.05 as of Aug. 01, 2026, which is 100% below its 10-year median of 0.40. GuruFocus rates STU:BMP with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 32 Medical Distribution companies, BMP Pharma Trading AG ranks better than 90.62% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, BMP Pharma Trading AG's PEG is 1. BMP Pharma Trading AG's 5-Year TTM EBITDA Growth Rate is 25.
BMP Pharma Trading AG's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.52. Therefore, the Peter Lynch Fair Value for today is €13.05.
The historical rank and industry rank for BMP Pharma Trading AG's Peter Lynch Fair Value or its related term are showing as below:
STU:BMP'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.11 Med: 0.4 Max: 0.97
Current: 0.48
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of BMP Pharma Trading AG was 0.97. The lowest was 0.11. And the median was 0.40.
STU:BMP's Price-to-Peter-Lynch-Fair-Value is ranked better than 90.62% of 32
companies
in the Medical Distribution industry
Industry Median: 1.35
vs STU:BMP: 0.48
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
BMP Pharma Trading AG (STU:BMP) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
BMP Pharma Trading AG's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
6.20
/
13.05
=
0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMP Pharma Trading AG Peter Lynch Fair Value Related Terms
BMP Pharma Trading AG Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for BMP Pharma Trading AG's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMP Pharma Trading AG Peter Lynch Fair Value Chart
STU:BMP vs MCK, COR, CAH: Peter Lynch Fair Value Comparison
For the Medical Distribution subindustry, BMP Pharma Trading AG's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BMP Pharma Trading AG Price-to-Peter-Lynch-Fair-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, BMP Pharma Trading AG's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where BMP Pharma Trading AG's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BMP Pharma Trading AG's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of €13.05 mean?
BMP Pharma Trading AG (STU:BMP) has a Peter Lynch Fair Value of €13.05 as of Aug. 01, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on BMP Pharma Trading AG and its competitors. This is 3163% above median its historical median of 0.40. Over the past decade, BMP Pharma Trading AG's Peter Lynch Fair Value has ranged from 0.11 to 0.97. According to the industry distribution chart, BMP Pharma Trading AG ranks #3 out of 32 companies in the Medical Distribution industry, placing it in the top 9.4%.
Is BMP Pharma Trading AG's Peter Lynch Fair Value too high?
BMP Pharma Trading AG's current Peter Lynch Fair Value of €13.05 is 3163% above median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.97. Based on the distribution chart, BMP Pharma Trading AG ranks #3 out of 32 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, BMP Pharma Trading AG has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BMP Pharma Trading AG's Peter Lynch Fair Value compare to MCK and COR?
According to the Medical Distribution industry distribution chart, BMP Pharma Trading AG ranks #3 out of 32 companies for Peter Lynch Fair Value. This places BMP Pharma Trading AG in the top 9% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 1.35. Historically, BMP Pharma Trading AG's own Peter Lynch Fair Value has ranged from 0.11 to 0.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Distribution company?
The median Peter Lynch Fair Value among Medical Distribution companies is 1.35, based on 32 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on BMP Pharma Trading AG and its competitors. For the Medical Distribution industry, the median Peter Lynch Fair Value is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BMP Pharma Trading AG's current Peter Lynch Fair Value is €13.05, which is 3163% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BMP Pharma Trading AG stock overvalued right now?
BMP Pharma Trading AG (STU:BMP) has a current Peter Lynch Fair Value of €13.05. The current Peter Lynch Fair Value is €13.05, which is 3163% above median its 10-year median of 0.40. BMP Pharma Trading AG's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For BMP Pharma Trading AG (STU:BMP), the current Peter Lynch Fair Value is €13.05 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BMP Pharma Trading AG is a German company engaged in trading of pharmaceutical raw materials, food supplement products, and veterinary raw materials. The services offered by the company include development of microbial processes, Transfer of biotechnological processes, Contract production of biotechnologically and biocatalysts and development of chiral syntheses.
36GF Score
Get the complete analysis for STU:BMP
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BMP has been successfully added to your 
